This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Apricus Biosciences Inc (APRI)

NASDAQ: Health Care

$0.95 -0.0480 | -4.81%
12/19/14 - 4:00 PM ET
  • Prev Close: 0.9980
  • Day's Open: 1.02
  • Volume: 667.26K
  • Avg Vol: 154.80K
  • Shares Outstanding: 43.62M
  • Mkt Cap: 46.24M
  • Div: --
  • Div Yield: --
  • P/E: N/A
  • EPS: -0.49
APRI Day's Range
$0.92
$1.03
APRI 52 Week Range
$0.98
$2.71
APRI Business Summary
Apricus Biosciences, Inc., a pharmaceutical company, focuses on the development and commercialization of novel therapeutics for men's and women's health. The company's lead product, Vitaros, has approved for the treatment of erectile dysfunction in Canada and Europe.View APRI key stats
APRI Performance as of Prev. Close
YTD
-60.00%
3-Mo
-40.11%
1-Yr
-48.82%
3-Yr
-78.50%
APRI EPS Performance
1-Yr Ago
-0.49
2-Yrs Ago
-1.16
3-Yrs Ago
-0.90
APRI Percentage in these ETFs
0.001%
0.000%
0.000%
0.000%
APRI News

APRI Apricus Biosciences Inc

Analysts Ratings for APRI

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 2 2 3 3
Moderate Buy 0 0 0 0
Hold 1 1 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET APRI ANALYST REPORT

Brokerage Partners

APRI Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs